Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source
Author(s) -
HansChristoph Diener,
Ralph L. Sacco,
J. Donald Easton,
Christopher B. Granger,
Richard A. Bernstein,
Shinichiro Uchiyama,
Jörg Kreuzer,
Lisa Cronin,
Otto W. Witte,
Claudia Grauer,
Martina Brueckmann,
M. A. Chernyatina,
Geoffrey A. Donnan,
José M. Ferro,
Martin Grond,
Bernd Kallmünzer,
Jerzy Krupiński,
ByungChul Lee,
Robin Lemmens,
Jaime Masjuán,
Miroslav Odinak,
Jeffrey L. Saver,
Peter D. Schellinger,
Danilo Toni,
Ḱazunori Toyoda
Publication year - 2019
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1813959
Subject(s) - embolic stroke , dabigatran , stroke (engine) , medicine , cardiology , atrial fibrillation , ischemic stroke , warfarin , engineering , mechanical engineering , ischemia
Cryptogenic strokes constitute 20 to 30% of ischemic strokes, and most cryptogenic strokes are considered to be embolic and of undetermined source. An earlier randomized trial showed that rivaroxaban is no more effective than aspirin in preventing recurrent stroke after a presumed embolic stroke from an undetermined source. Whether dabigatran would be effective in preventing recurrent strokes after this type of stroke was unclear.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom